Dendritic Killer Cell-based Immunotherapy for Solid Tumors

Hepatocellular Carcinoma Clinical Trial

Official title:

Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02882659
• Other study ID #: 2013-07-026B
• Status: Active, not recruiting
• Phase: Phase 1
• First received: August 18, 2016
• Last updated: August 24, 2016
• Start date: August 2014
• Est. completion date: December 2017

Study information

• Verified date: August 2016
• Source: FullHope Biomedical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan : Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 18
• Est. completion date: December 2017
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Capable and willing of providing signed informed consent before study

2. Patient age =20 at date of consent

3. Performance status (ECOG) =2

4. Patients have a life expectancy of > 3 months

5. Patients agree to be in compliant to clinical protocol planned treatment plan

6. Histologically confirmed metastatic solid tumor, including colon cancer, gastric cancer, pancreatic cancer, bile duct cancer, liver cancer

7. Patient with histological and conventional imaging proven measurable lesion

8. Patients not pregnant. All male and female patients with reproduction ability should use appropriate contraception method(s) during the study period

9. Patient is not currently under immunosuppressive treatment for previous or recurred autoimmune disease

10. Patient should have received and failed prior standard cancer therapies (according to TVGH standard cancer treatment procedures, or National Comprehensive Cancer Network clinical practice guidelines in oncology)

11. Patient with adequate hematology function:

Absolute neutrophil count (ANC) = 1,500 cells Total white blood cell (WBC) = 3,000 cells /mm3 Hemoglobin = 9 g/dl Platelets = 100,000 counts /mm3

12. Patient with adequate hepatic and renal function Serum creatinine = 1.5X Upper Limit of Normal (ULN) Total bilirubin (TB) = 1.5X ULN, or = 2.5X ULN for patients with primary HCC or liver metastasis ALT and AST = 2.5X ULN, or = 5X ULN for patients with primary HCC or liver metastasis Alkaline phosphatase (ALP) = 5X ULN

13. Patient showing negative response in syphilis, HIV, HBV and HCV test

Exclusion Criteria:

1. Any other investigational drug used within 28 days prior to first DKC administration

2. Patient with known brain metastasis or metastasis to central nervous system

3. Patient with pulmonary fibrosis

4. Patient with pleural effusion or as cites correspond to CTCAE grading > 2

5. Patient with uncontrolled disease including but not limit to cardiovascular disease, liver disease, renal disease or infectious disease

6. Patients being diagnosed with any cognitive or psychiatric illness

7. Patient not suitable to participate the trial for safety concerns as judged by the investigator

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Colorectal Neoplasms
• Hepatocellular Carcinoma
• Neoplasm Metastasis
• Neoplasms

Intervention

Biological:
• Dendritic Killer Cell (DKC)
DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
FullHope Biomedical Co., Ltd.	Taipei Veterans General Hospital, Taiwan

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of DKC as assessed by adverse event (AE)	The coding system used for AE is MedDRA. Only treatment-emergent adverse events (TEAEs) are considered for primary endpoint. Frequency table of subjects with pre-treatment and treatment-emergent AE are presented by each cohort and overall trial. AE incidents are summarized descriptively by system organ class and preferred term using MedDRA for each cohort and overall trial.	Entire treatment period (cycle 1-5, 116 +/- 4 days) and follow-up period (452 +/- 4 days)	Yes
Primary	Safety of DKC as assessed by serious adverse event (SAE)	Serious adverse event incidence is summarized descriptively by system organ class and preferred term for each cohort and overall trial. The causality of SAEs will be assessed by the principal investigator for its relationship to study medication.	Entire treatment period (cycle 1-5, 116 +/- 4 days) and follow-up period (452 +/- 4 days)	Yes
Primary	Safety of DKC as assessed by dose-limiting toxicity (DLT)	DLT is defined as Grade ? 3 (according to NCI-CTCAE 4.03 grading system), study medication-related (i.e. with causality determined as at least possibly related to study medication), and worsened in comparison to baseline (pre-treatment condition). DLT is determined after first infusion cycle and maximum tolerated dose (MTD) is determined as the highest dose without DLT. DLT is defined by the items listed below: Blood and lymphatic system disorders: Grade ? 3 of (1) Any febrile neutropenia, (2) Leukocytosis, (3) Anemia; Other disorders: Grade ? 3 of (1) Diarrhea, (2) Vomiting, (3) Fever, (4) Nausea, (5) Anaphylaxis	Entire treatment period (cycle 1-5, 116 +/- 4 days) and follow-up period (452 +/- 4 days)	Yes
Primary	Safety of DKC as assessed by combining with concomitant anticancer treatment	The subjects enrolled in the study are cancer patients, who were treated with anticancer drugs before, and possibly during, DKC immunotherapy. Potential adverse drug-drug interaction (DDI) is monitored during treatment and follow-up period.	Entire treatment period (cycle 1-5, 116 +/- 4 days) and follow-up period (452 +/- 4 days)	Yes
Primary	Safety of DKC as assessed by laboratory examinations	For each cohort, there are 5 baselines (taken 9 days before infusion) for 5 infusion cycles, and there are 2 evaluation time points in each infusion cycle (at end of first week and second week after infusion) and 4 in the follow-up period (at every 12 weeks). The laboratory evaluation results are tabulated in two aspects: 1) the percentage changes between each evaluation and corresponding baselines, and 2) the mean baseline values of each cycle in each cohort. Laboratory results regarding different functional categories are described separately in following areas.; Hematology related items: Hb (g/dL), WBC (count/uL), Platelet (x 10^3 count/uL), ANC (count/uL); Liver function related items: C-RP (mg/dL), Glucose AC (mg/dL), Total Bilirubin (mg/dL), AST (U/L), ALT (U/L), LDH (U/L), ALP (U/L), gammaGT (U/L); Serum lipids and proteins, renal function, and electrolytes related items: HDL-C (mg/dL), Total Cholesterol (mg/dL), Triglyceride (mg/dL), Creatinine (mg/dL), BUN (mg/dL)	Entire treatment period (cycle 1-5, 116 +/- 4 days) and follow-up period (452 +/- 4 days)	Yes
Secondary	Efficacy of DKC as assessed by tumor specific T cell response	The tumor specific T cell response was assessed by the detection of CD3+CD8+CD69+IFN-gamma+ T lymphocytes in percentage relative to total peripheral blood mononuclear cells (PBMCs). Baseline value was measured before first infusion cycle, and subsequent evaluation time points were measured right after infusion cycles 2, 3, and 4.	Entire treatment period (cycle 1-5, 116 +/- 4 days)	No
Secondary	Efficacy of DKC as assessed by change in quality of life	The quality of life as assessed by the WHO QoL-BREF questionnaire, and the transformed scores (0-100) was used to facilitate the interpretation. Baseline value was measured before first infusion cycle, and evaluation time points were taken right after infusion cycles 2, 3, 4, and 5. During the follow-up period, evaluation time points were taken at every 12 weeks for a total of 4 time points.	Entire treatment period (cycle 1-5, 116 +/- 4 days) and follow-up period (452 +/- 4 days)	No